CLASS II ONGOING Device recall · Reported 18 Sep 2024 · FDA Enforcement Report

Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use recalled

Siemens Healthcare Diagnostics is recalling Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of, distributed nationwide in the US. The recall was initiated on 26 Jul 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: (01)00630414598178(10)55974535(17)20240914 Kit Lot: 55974535, 55975535

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-3100-2024
FDA event ID
95118
Recalling firm
Siemens Healthcare Diagnostics, East Walpole, MA
Classification
Class II
Status
Ongoing
Recall initiated
26 Jul 2024
FDA classified
11 Sep 2024
Reported
18 Sep 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

26 Jul 2024Recall initiated by company
11 Sep 2024Classified by FDA+47 days
18 Sep 2024Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum using the Atellica CI and Atellica IM Analyzers SMN: 10995490

Where it was distributed

Worldwide - US Nationwide distribution

Nationwide

Questions about this recall

Why was it recalled?

Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.

Which lots are affected?

UDI-DI: (01)00630414598178(10)55974535(17)20240914 Kit Lot: 55974535, 55975535

Where was it sold?

Worldwide - US Nationwide distribution

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

4 other products · FDA event 95118

More recalls from Siemens Healthcare Diagnostics

All 694

Other Test Kits & Diagnostics recalls

All 2,656